Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)

NCT03694171 | Completed Results

• 1 other identifier: IB2013 INCAPAC
• Study Type: observational
• Target: 450
• Locations: 1 country
• Sites: 1

Brief Summary

The growing incidence of cancer associated to an aging population represents an epidemiologic reality that requires questioning access to care and prognosis in elderly with cancer, for which disparities have been highlighted. However, generally speaking, studies are limited in that they overlook geriatric-specific factors. The aim of this work was to study sociodemographic, socioeconomic and clinical determinants of access to care (cancer stage, cancer treatment) and prognosis (functional decline, survival) in elderly cancer patients.

Conditions

Cancer

Keywords

Elderly; Cancer; Cohort study; Cancer registry; Access to care; Cancer stage; Cancer treatment; Prognosis; Functional decline; Survival

Outcome Measures

Primary Outcomes (2)

• Proportion of Patients Being Receiving Treatment Administration After Diagnosis

  Treatment administration was defined as any cancer treatment (versus no treatment) including curative, palliative and symptomatic treatments. This information was registered by registries and qualified as unknown when no information was available about treatment receipt.

  At diagnosis

• The Probability of Being Dead at One Year

  The probability of being dead with or without receiving cancer treatment at least once (death)

  one year after diagnosis

Study Arms (1)

Older patients with cancer

Subjects i) aged 65 years and over from the PAQUID, the 3City or the AMI study; ii) alive on January 1st 2005 (common start date of tumor recording); iii) resident in Gironde; and iv) with a validated cancer diagnosis recorded in one of the cancer registries from January 1st 2005 to December 31st 2014. We included all invasive malignant tumors (including skin tumors) and benign tumors of the central nervous system. For patients with multiple tumors, only one was considered: i) the first one diagnosed if there were several tumors with a minimum of a 6 months interval between their diagnosis, ii) the one with the worse prognosis if there were several tumors diagnosed within less than 6 months.

Other: Any cancer treatment

Interventions

Any cancer treatment OTHER

Older patients with cancer

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects aged 65 and over with a diagnosis of cancer recorded in one of the cancer registries in Gironde, French department.

* Age ≥ 65 years * Alive on January 1st 2005 ( PAQUID or 3-City cohorts) or included in the AMI cohort study * Cancer diagnosis recorded in one of the cancer registries in Gironde, French department

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Institut Bergonié: lead
• Institut National de la Santé Et de la Recherche Médicale, France: collaborator
• University of Bordeaux: collaborator

Study Sites (1)

Institut Bergonié

Bordeaux, 33076, France

Location

Related Publications (2)

• Galvin A, Helmer C, Coureau G, Amadeo B, Joly P, Sabathe C, Monnereau A, Baldi I, Rainfray M, Soubeyran P, Delva F, Mathoulin-Pelissier S. Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study). Cancer Epidemiol. 2018 Aug;55:39-44. doi: 10.1016/j.canep.2018.04.013. Epub 2018 May 25.

  PMID: 29763754 RESULT

• Galvin A, Delva F, Helmer C, Rainfray M, Bellera C, Rondeau V, Soubeyran P, Coureau G, Mathoulin-Pelissier S. Sociodemographic, socioeconomic, and clinical determinants of survival in patients with cancer: A systematic review of the literature focused on the elderly. J Geriatr Oncol. 2018 Jan;9(1):6-14. doi: 10.1016/j.jgo.2017.07.007. Epub 2017 Oct 10.

  PMID: 29030150 RESULT

MeSH Terms

Conditions

Neoplasms

Results Point of Contact

• Title: Simone Mathoulin-Pélissier
• Organization: Institut Bergonié, Comprehensive Cancer Center, Bordeaux, FR

s.mathoulin@bordeaux.unicancer.fr

+33 5 56 33 33 33

Study Officials

• Simone Mathoulin-Pelissier, MD-PhD

  Institut Bergonié

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2018
• First Posted: October 3, 2018
• Study Start: November 1, 2013
• Primary Completion: November 1, 2016
• Study Completion: November 1, 2017
• Last Updated: October 3, 2025
• Results First Posted: September 11, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)